Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Semaglutide presents a promising, multi-targeted therapeutic option for addressing the hepatic and systemic consequences of MASH, though final conclusions on long-term clinical outcomes await the ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...